In July 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) published an important Drug Safety Update regarding botulinum toxin type A products. The update strengthens existing warnings about the rare but serious risk of iatrogenic botulism, including several important reminders for both practitioners and patients. Among the key points are:
- Cases of iatrogenic botulism following both cosmetic and therapeutic botulinum toxin treatments remain very rare, but they can occur if the effects of the toxin spread beyond the intended treatment area.
- Symptoms typically develop between four and eight days after treatment, although in some cases they may not appear until up to four weeks later.
- Patients should seek immediate emergency medical attention if they experience symptoms such as difficulty swallowing, slurred speech, difficulty breathing, severe eyelid drooping or widespread muscle weakness after treatment.
- The risk may be higher in patients with certain underlying neurological conditions, when unusually high doses are used, when products are injected outside their licensed indications or approved treatment sites, or when counterfeit or unauthorised products are used.
- The MHRA is updating the prescribing information and patient information leaflets for all authorised botulinum toxin type A products to further strengthen these warnings.
- Practitioners are reminded to use only UK-authorised products, follow the manufacturer’s licensed guidance on dosing and administration, ensure anyone administering the medicine is appropriately trained, and report suspected adverse reactions through the Yellow Card Scheme.
- The MHRA has also highlighted its ongoing investigations into the illegal sale and supply of counterfeit and unlicensed botulinum toxin products following an increase in hospital admissions linked to these products.
The update isn’t intended to alarm patients; it reinforces the importance of appropriate prescribing, thorough patient assessment, recognised training and using licensed medicines supplied through legitimate channels.
Whenever guidance like this is updated, it’s understandable that patients have questions. ‘Does this mean anti-wrinkle injections have suddenly become unsafe? Should people be worried?’ The short answer is no. But it is a timely reminder that, while botulinum toxin has an excellent safety profile when used appropriately, it is still a prescription medicine that deserves respect.
One of the challenges in aesthetics is that treatments can look deceptively simple. A few small injections may take only minutes, and because they’re so common, it’s easy to forget that we’re using a medication capable of temporarily blocking nerve signals. Like any medicine, it needs the right patient, the right dose, the right product and the right practitioner.
Iatrogenic botulism is exceptionally uncommon, but it occurs when botulinum toxin spreads beyond the intended muscles and begins affecting other parts of the body. The symptoms are very different from the expected effects of cosmetic treatment, as the toxin can interfere with muscles involved in swallowing, speaking or breathing.
It’s important to keep that risk in perspective. Millions of botulinum toxin treatments are performed worldwide every year, and serious complications remain extremely rare. However, “rare” should never mean ignored. Good medicine relies on recognising uncommon risks and ensuring patients know what to do if something unexpected happens.
The warning highlights several factors that may increase risk, including higher treatment doses, treatment outside licensed indications, injections into unapproved areas, certain underlying medical conditions and the use of counterfeit or unauthorised products. A thorough medical history helps identify neurological conditions or swallowing disorders that could increase risk.
Another important point within the MHRA guidance relates to the products themselves. Botulinum toxin is a prescription-only medicine in the UK, and not all products are the same. Different brands have different dosing systems, approved indications and administration guidelines. Their units are not interchangeable, which is one reason why proper training and familiarity with the chosen product are so important.
The MHRA also continues to investigate the illegal sale of counterfeit and unlicensed botulinum toxin products following an increase in hospital admissions linked to their use.This is probably the most worrying aspect of the update. Licensed UK products have undergone extensive regulatory assessment for quality, safety and effectiveness. Counterfeit or unauthorised products simply don’t offer those same precautions.
For practitioners, I think this update serves as a useful reminder that safe practice means following licensed guidance, understanding anatomy, prescribing responsibly, recognising complications early and making sure patients leave fully informed about what is normal, what isn’t and when they should seek urgent medical advice.
I also hope the update encourages patients to ask more questions before choosing where to have treatment.
- Who is prescribing the medication?
- Is the product licensed for use in the UK?
- What training and qualifications does the practitioner have?
- What happens if something goes wrong?
The vast majority of aesthetic treatments are carried out safely every day by conscientious healthcare professionals. Updates such as this shouldn’t create unnecessary fear, but they should reinforce the importance of choosing practitioners who prioritise patient welfare over convenience, price or trends.
